Letter to Customers —
AI Roadmap for Leucine

February 22, 2026

Dear customers and partners,

Every once in a while, a new technology arrives and it changes everything. Not incrementally. Not at the margins. It redraws the entire landscape. We believe agentic AI is that technology for pharmaceutical manufacturing — and Leucine is at the centre of it.

This letter is about where we are, what we have built, why it matters, and where we are going together.

I.

Pharma has spent decades layering software on top of paper processes. An electronic batch record here. A cleaning validation spreadsheet there. A deviation tracker in one system, a CAPA workflow in another, audit findings in a third. Every tool solves one problem and creates two more — data silos, reconciliation overhead, and an ever-growing attack surface for compliance failures.

The industry doesn't have a technology problem. It has an architecture problem. Dozens of point solutions, none of which share a common data model, none of which understand the relationships between a batch record and a deviation and a cleaning protocol and an FDA observation. The data exists. The intelligence doesn't — because the systems were never designed to think together.

This is what we set out to change.

II.

LeucineOS is not another point solution. It is a unified, ontology-based platform — a single data architecture where every entity in pharmaceutical manufacturing (batches, deviations, CAPAs, cleaning protocols, audit observations, regulatory signals) lives in one connected graph. When a deviation occurs on a production line, the platform already knows the batch history, the cleaning status, the equipment lineage, the regulatory precedent. It doesn't need to query five systems and wait for someone to reconcile the answers. The knowledge is structural.

This is the foundation. And everything we are building next sits on top of it.

III.

Now here is where it gets interesting.

Most companies adding AI to pharma are bolting a language model onto an existing workflow and calling it intelligent. A chatbot that answers questions about your SOPs. A classifier that flags potential deviations. These are useful. They are also insufficient. They are point AI solutions — and they inherit all the limitations of the point software architecture underneath them.

A deviation-detection model that doesn't understand your cleaning history is blind. A batch-review assistant that can't see your CAPA trends is guessing. An audit preparation tool that doesn't know your FDA observation history is performing theatre. AI without unified data is just pattern matching on fragments.

We took a fundamentally different approach. We built the ontology first — the unified data architecture that captures the full reality of pharmaceutical manufacturing operations. Then we built the agentic layer on top of it.

The result is an agentic platform where AI agents don't just respond to queries. They observe, reason, investigate, and act — across the full breadth of your manufacturing data. They understand context because the platform gives them context. They see connections because the data model encodes connections. They get smarter over time because every interaction, every decision, every outcome feeds back into the same unified graph.

IV.

Let me be specific about what this means today.

We have released the Leucine agentic platform into the market. It is built on MCP (Model Context Protocol) — the emerging open standard for connecting AI agents to structured data and tools. It incorporates agentic orchestration, tool use, memory, and reasoning into a single runtime that operates within GMP constraints. 21 CFR Part 11 compliant. Fully auditable. Every agent action logged, every decision traceable.

This is not a research prototype. It is the most modern agentic infrastructure available for regulated manufacturing.

The platform serves multiple use cases through a single architecture:

• Autonomous deviation detection. Agents that monitor batch data in real time, identify anomalies against historical baselines across sites, and generate preliminary investigation reports — complete with root cause hypotheses and supporting data — before a human reviewer opens the record. Not flagging. Investigating.
• Predictive CAPA. Agents that analyse deviation patterns across your entire facility network to identify systemic issues before they become repeat observations. When an FDA investigator asks "what are you doing to prevent recurrence?", the system has already identified the pattern, recommended the corrective action, and tracked its implementation.
• Intelligent batch review. Review agents that verify batch records against specifications, cross-reference with cleaning and equipment data, flag exceptions by severity, and prepare review-ready summaries. Workflow digitisation alone compresses batch review dramatically. Agentic review takes that further — and catches what human reviewers miss at 2 AM.
• Regulatory intelligence. FDA Tracker is expanding into a multi-authority regulatory intelligence platform — covering FDA, EMA, MHRA, and PMDA enforcement signals. Agents that correlate external regulatory patterns with your internal quality data to predict where inspection risk is rising.
• Cleaning validation. Next-generation CLEEN with automated HBEL calculations, protocol auto-generation, and cross-facility worst-case analysis. Agents that maintain your validation lifecycle continuously, not just during revalidation cycles.

These are the capabilities we are delivering now. And we are building more — extending into more complex use cases like supplier quality management, change control orchestration, and environmental monitoring intelligence. Each new capability benefits from the same unified ontology, the same agentic infrastructure, the same compliance architecture.

V.

The vision is simple to state and ambitious to execute: we are building a central agentic workforce for pharmaceutical manufacturing.

Think about what that means. Today, your quality organisation employs hundreds of people who spend most of their time on data gathering, reconciliation, documentation, and pattern recognition across disconnected systems. They are brilliant professionals doing mechanical work because the software forces them to. Every deviation investigation starts with the same tedious data collection. Every batch review follows the same manual verification steps. Every audit preparation involves the same frantic scramble to assemble records from disparate sources.

The agentic workforce handles all of this. Not by replacing your quality professionals — by giving them a team of AI agents that does the mechanical work at machine speed, with machine consistency, while maintaining full GMP compliance. Your people focus on the decisions that actually require human judgement. The agents handle everything else.

Cross-site intelligence is central to this vision. Today, a deviation at one facility doesn't inform risk assessments at another. A cleaning failure in one plant doesn't update the worst-case matrix at a sister site. An FDA observation at a competitor doesn't trigger a proactive review of your own operations. In the system we are building, all of this happens automatically. Every signal, every outcome, every learning flows through the unified ontology and makes every agent, at every site, smarter.

This is the difference between point AI and platform AI. Point solutions optimise one workflow. Platform AI optimises the entire operation — because it sees the entire operation. The compound effect of this is enormous. Each new use case doesn't just add value for itself. It enriches the data that makes every other use case more intelligent. The platform gets better at deviation detection because it understands your CAPA outcomes. It gets better at batch review because it learns from your cleaning validation data. It gets better at regulatory prediction because it correlates your internal quality signals with external enforcement patterns.

Point solutions can never do this. They are islands. And no amount of integration middleware turns islands into a continent.

VI.

We believe the next five years will fundamentally reshape pharmaceutical manufacturing. The companies that build their quality operations on a unified agentic platform will operate at a level of compliance, speed, and intelligence that will be impossible to replicate with the current generation of disconnected tools. This is not about marginal improvement. It is about competitive separation.

Regulatory agencies are watching. The FDA's increasing focus on data integrity, predictive quality, and continuous manufacturing is not a coincidence. They want to see systems that don't just record what happened — systems that understand why it happened and what to do about it. That is exactly what an agentic platform delivers.

We are building Leucine to be the company that defines this era. The AI-native operating system for pharmaceutical manufacturing. The platform that turns compliance from a cost centre into a competitive advantage. The agentic workforce that makes every quality professional ten times more effective.

We have the foundation. We have the architecture. We have the conviction. And we are just getting started.

Thank you for building this with us.

Sincerely,